SELLAS partner GenFleet doses first patient in Phase Ib/II combo trial of GFH009 + BRUKINSA for DLBCL

SELLAS Life Sciences Group, Inc.

GenFleet entered clinical trial collaboration with BeiGene for GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib).
First patient dosed in open-label, single-arm, multi-center Phase Ib/II trial for relapsed/refractory DLBCL in China.
Trial evaluates safety and efficacy of the combination therapy; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.